Interrupted time series analysis in drug utilization research is increasing: Systematic review and recommendations

Journal of Clinical Epidemiology

Volumn 68, Issue 8, 2015, Pages 950-956

  Jandoc, Racquel ^a   Burden, Andrea M ^a   Mamdani, Muhammad ^a,b,c   Lévesque, Linda E ^d   Cadarette, Suzanne M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

ARIMA; Drug utilization; Pharmacoepidemiology; Review; Segmented regression; Time series

Indexed keywords

NEW DRUG;

CONFERENCE PAPER; DRUG LEGISLATION; DRUG UTILIZATION; HUMAN; MEDLINE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); TIME SERIES ANALYSIS; TOTAL QUALITY MANAGEMENT; WEB OF SCIENCE; EPIDEMIOLOGY; METHODOLOGY;

DRUG UTILIZATION; HUMANS; INTERRUPTED TIME SERIES ANALYSIS; RESEARCH DESIGN;

EID: 84933181462     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2014.12.018     Document Type: Conference Paper

References (25)

1. J. Grimshaw, M. Campbell, M. Eccles, and N. Steen Experimental and quasi-experimental designs for evaluating guideline implementation strategies Fam Pract 17 Suppl 1 2000 S11 S16
2. A.D. Harris, J.C. McGregor, E.N. Perencevich, J.P. Furuno, J.K. Zhu, and D.E. Peterson The use and interpretation of quasi-experimental studies in medical informatics J Am Med Inform Assoc 13 2006 16 23
3. A.K. Wagner, S.B. Soumerai, F. Zhang, and D. Ross-Degnan Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 27 2002 299 309
4. B.A. Briesacher, S.B. Soumerai, F. Zhang, S. Toh, S.E. Andrade, and J.L. Wagner A critical review of methods to evaluate the impact of FDA regulatory actions Pharmacoepidemiol Drug Saf 22 2013 986 994
5. R.B. Penfold, and F. Zhang Use of interrupted time series analysis in evaluating health care quality improvements Acad Pediatr 13 2013 S38 S44
6. Cochrane Effective Practice and Organisation of Care Review Group. Interrupted time series analyses. 2013. Available at http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/21%20Interrupted%20time%20series%20analyses%202013%2008%2012.pdf. Accessed September 1, 2014.
7. D. Gillings, D. Makuc, and E. Siegel Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care Am J Public Health 71 1981 38 46
8. M. Lagarde How to do (or not to do)... Assessing the impact of a policy change with routine longitudinal data Health Policy Plan 27 2012 76 83
9. G.M. Ljung, and G.E.P. Box On a measure of lack of fit in time series models Biometrika 67 1987 297 303
10. J. Durbin, and G. Watson Testing for serial correlation in least squares regression I Biometrika 37 1950 409 428
11. D.A. Dickey, and W.A. Fuller Distribution of the estimators for autoregressive time series with a unit root J Am Stat Assoc 1979 427 431
12. F. Zhang, A.K. Wagner, and D. Ross-Degnan Simulation-based power calculation for designing interrupted time series analyses of health policy interventions J Clin Epidemiol 64 2011 1252 1261
13. J. Gottman, and R. Rushe The analysis of change: issues, fallacies, and new ideas J Consult Clin Psychol 61 1993 907 910
14. M.M. Jirovec Time-series analysis in nursing research: ARIMA modeling Nurs Res 35 1986 315 319
15. Cochrane Effective Practice and Organisation of Care Review Group. Suggested risk of bias criteria for EPOC reviews: risk of bias for interrupted time series (ITS) studies. 2013. Available at http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.pdf. Accessed September 1, 2014.
16. F. Zhang, A.K. Wagner, S.B. Soumerai, and D. Ross-Degnan Methods for estimating confidence intervals in interrupted time series analyses of health interventions J Clin Epidemiol 62 2009 143 148
17. G.P. Consiglio, A.M. Burden, M. Maclure, L. McCarthy, and S.M. Cadarette Case-crossover study design in pharmacoepidemiology: systematic review and recommendations Pharmacoepidemiol Drug Saf 22 2013 1146 1153
18. M. Tadrous, J.J. Gagne, T. Sturmer, and S.M. Cadarette Disease risk score as a confounder summary method: systematic review and recommendations Pharmacoepidemiol Drug Saf 22 2013 122 129
19. G.E.P. Box, and G.M. Jenkins Time series analysis: forecasting and control 1976 Holden-Day San Francisco, CA
20. M.B. Mandell Obtaining interval estimates of policy impacts from interrupted time-series Eval Rev 11 1987 631 659
21. E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gotzsche, and J.P. Vandenbroucke The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies J Clin Epidemiol 61 2008 344 349
22. L.F. Garabedian, D. Ross-Degnan, S. Ratanawijitrasin, P. Stephens, and A.K. Wagner Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series study BMJ Open 2 2012 e001686
23. D.M. Gorman, and J. Charles Huber Jr. Do medical cannabis laws encourage cannabis use? Int J Drug Policy 18 2007 160 167
24. M.D. Huesch, T. Ostbye, and M.K. Ong Measuring the effect of policy interventions at the population level: some methodological concerns Health Econ 21 2012 1234 1249
25. C.J. Green, M. Maclure, P.M. Fortin, C.R. Ramsay, M. Aaserud, and S. Bardal Pharmaceutical policies: effects of restrictions on reimbursement Cochrane Database Syst Rev 2010 CD008654